http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20170004013-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-56 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-12 |
| filingDate | 2015-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc97cab6c6a005e32224fb2ef592e82d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_acfdeacfcc9e535e74d2fec830e5bd95 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc9f9cbb162afca27e17d0e0de210e59 |
| publicationDate | 2017-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20170004013-A |
| titleOfInvention | Peptides as oxytocin agonists |
| abstract | The present invention relates to compounds of formula (I), or pharmaceutically acceptable acid addition salts thereof, racemic mixtures or the corresponding enantiomers and / or optical isomers thereof: Formula I In this formula, R < 1 > is hydrogen, lower alkyl or cycloalkyl, R < 2 > is hydrogen, R 1 and R 2 together with the N and C atoms to which they are attached form a pyrrolidine ring optionally substituted with one or two F atoms or hydroxy, or form an azetidine or piperazine ring; R 3 is hydrogen, lower alkyl, hydroxy lower alkyl, substituted by - (CH 2) 2 C ( O) NH 2, benzyl, phenyl, -CH 2 -5 membered aromatic heterocyclic group, CH 2 - indolyl, -CH 2 - cycloalkyl, cycloalkyl or - (CH 2) 2 -S- and lower alkyl; R < 3 > is hydrogen or lower alkyl; X is -C (O) -CHR 4 -CHR 4 ' -C (O) -NH-CH 2 -; R 4 and R 4 ' are hydrogen, or one of R 4 and R 4' is amino; o is 0 or 1. The compounds of the present invention are useful for the treatment of oxytocin receptors for the treatment of anxiety, schizophrenia, mental illness, memory loss, alcohol withdrawal symptoms, drug addiction or Prader-Willi Syndrome including stress, anxiety disorder or depression including autism, post traumatic stress disorder It has been revealed that it is an action. |
| priorityDate | 2014-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 155.